PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 11796829-11 2002 Treatment of angiotensin II-infused rats with an iron chelator, deferoxamine, blocked the abnormal iron deposition in kidneys and also the induced expression of HO-1 and ferritin expression. Deferoxamine 64-76 heme oxygenase 1 Rattus norvegicus 161-165 21725753-9 2011 DFX also reduced the number of ferritin (p<0.05) and HO-1 (p<0.01) positive cells in the ipsilateral basal ganglia. Deferoxamine 0-3 heme oxygenase 1 Rattus norvegicus 56-60 11579132-6 2001 The presence of the iron chelators phenanthroline or deferoxamine (DFO), which previously has been shown to protect oligodendrocytes from oxidative stress-induced onset of apoptosis, caused a marked stimulation of HSP32 without affecting HSP70. Deferoxamine 53-65 heme oxygenase 1 Rattus norvegicus 214-219 11579132-6 2001 The presence of the iron chelators phenanthroline or deferoxamine (DFO), which previously has been shown to protect oligodendrocytes from oxidative stress-induced onset of apoptosis, caused a marked stimulation of HSP32 without affecting HSP70. Deferoxamine 67-70 heme oxygenase 1 Rattus norvegicus 214-219 11579132-7 2001 This indicates that DFO possibly exerts its protective role by directly influencing the antioxidant capacity of HO-1. Deferoxamine 20-23 heme oxygenase 1 Rattus norvegicus 112-116 31082547-7 2019 RESULTS: The results showed that administration of DFO delayed erythrocytes lysis, reduced iron deposition, reduced reactive oxygen species generation, reduced heme oxygenase-1 expression, and alleviated brain injury such as neuron degeneration and myelin sheath injury. Deferoxamine 51-54 heme oxygenase 1 Rattus norvegicus 160-176 24935175-11 2014 Deferoxamine treatment attenuated TBI-induced hydrocephalus and heme oxygenase-1 upregulation. Deferoxamine 0-12 heme oxygenase 1 Rattus norvegicus 64-80 21725753-10 2011 However, DFX had no effect on brain GFAP and OX-6 immunoreactivity 2 months after ICH.In conclusion, DFX reduces cavity size, neurological deficits, and immunoreactivity for ferritin and HO-1 after ICH in aged rats, supporting the suggestion that DFX may reduce brain injury in ICH patients. Deferoxamine 101-104 heme oxygenase 1 Rattus norvegicus 187-191 21725753-10 2011 However, DFX had no effect on brain GFAP and OX-6 immunoreactivity 2 months after ICH.In conclusion, DFX reduces cavity size, neurological deficits, and immunoreactivity for ferritin and HO-1 after ICH in aged rats, supporting the suggestion that DFX may reduce brain injury in ICH patients. Deferoxamine 101-104 heme oxygenase 1 Rattus norvegicus 187-191 21725755-6 2011 Western blotting showed that levels of HSP-32 were reduced in the heart after ICH (p<0.05), and this reduction was normalized by DFX (p<0.05). Deferoxamine 132-135 heme oxygenase 1 Rattus norvegicus 39-45 21725755-11 2011 Deferoxamine treatment has different effects on the expression of HSP-27 and HSP-32. Deferoxamine 0-12 heme oxygenase 1 Rattus norvegicus 77-83 19581022-7 2009 Indeed, DFO reduced markedly reactive oxygen species formation, increased the expression of hemeoxygenase-1 and improved iron management through regulation of transferrin receptor and ferritin. Deferoxamine 8-11 heme oxygenase 1 Rattus norvegicus 92-107